Heart disease is the leading cause of death in the U.S., claiming over 1,900 lives each day, according to the American Heart Association. Every year, February is recognised as American Heart Month to raise awareness about heart health. Meanwhile, several drugs are also scheduled for FDA review this February. Will they pass the regulatory muster, or will they be sent back to the drawing board?
Let's take a look at the biotech stocks facing the FDA decision next month.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com